Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

Next Previous
X
Search
Trial Profile

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexmarilimab (Primary) ; Azacitidine; Azacitidine; Venetoclax
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms BEXMAB
  • Sponsors Faron Pharmaceuticals

    • Most Recent Events

    • 27 Aug 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
    • 27 Aug 2024 Planned primary completion date changed from 31 Dec 2024 to 1 Apr 2025.
    • 16 Apr 2024 According to a Faron Pharmaceuticals media release, Initial data from ongoing Phase 2 part of this trial anticipated next month (during the week commencing 20 May 2024.).This data readout will be important for ongoing partnering discussions and the major upcoming industry events that Faron will be attending, including the American Society for Clinical Oncology (ASCO) annual meeting and the Bio International Convention, taking place in June 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top